ALPMY - Astellas CiRA advance research on medical use of iPS cells
2023-04-12 04:33:45 ET
- Astellas Pharma ( OTCPK:ALPMY ) ( OTCPK:ALPMF ) and the Center for iPS Cell Research and Application (CiRA), Kyoto University entered the second phase of a joint research agreement to promote the use of differentiated cells and tissues derived from human induced pluripotent stem cells (iPS cells) and to create medical solutions.
- During the first phase, between July 2017 and March 2023, the two conducted joint research on drug discovery applications of iPS cells.
- In the second phase, the two will build on their past efforts and use digital technology into a technological platform for differentiated cells and tissues derived from iPS cells to accelerate drug discovery and develop the technology to cover a range of medical applications, the company added.
- For the joint research, CiRA installed Astellas' cellular drug discovery platform called Mahol-A-Ba.
- The two parties will work to construct digital protocols for Mahol-A-Ba to develop a high-quality and reproducible differentiation induction method and create a library of differentiated cells.
For further details see:
Astellas, CiRA, advance research on medical use of iPS cells